Neurosense Therapeutics Ltd Stock Alpha and Beta Analysis
| NRSNW Stock | USD 0.34 0.00 0.00% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as NeuroSense Therapeutics Ltd. It also helps investors analyze the systematic and unsystematic risks associated with investing in NeuroSense Therapeutics over a specified time horizon. Remember, high NeuroSense Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to NeuroSense Therapeutics' market risk premium analysis include:
Beta (0.57) | Alpha 0.57 | Risk 20.5 | Sharpe Ratio 0.071 | Expected Return 1.46 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
NeuroSense | Build AI portfolio with NeuroSense Stock |
NeuroSense Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. NeuroSense Therapeutics market risk premium is the additional return an investor will receive from holding NeuroSense Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in NeuroSense Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate NeuroSense Therapeutics' performance over market.| α | 0.57 | β | -0.57 |
NeuroSense Therapeutics Fundamentals Vs Peers
Comparing NeuroSense Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze NeuroSense Therapeutics' direct or indirect competition across all of the common fundamentals between NeuroSense Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as NeuroSense Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of NeuroSense Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing NeuroSense Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare NeuroSense Therapeutics to competition |
| Fundamentals | NeuroSense Therapeutics | Peer Average |
| Return On Equity | -24.78 | -0.31 |
| Return On Asset | -3.04 | -0.14 |
| Number Of Shares Shorted | 9.02 K | 4.71 M |
| EBITDA | (9.88 M) | 3.9 B |
| Net Income | (10.21 M) | 570.98 M |
| Cash And Equivalents | 994 K | 2.7 B |
| Cash Per Share | 0.13 X | 5.01 X |
NeuroSense Therapeutics Opportunities
NeuroSense Therapeutics Return and Market Media
The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Can NeuroSense Therapeutics Ltd. stock ride next bull market cycle - July 2025 Catalysts AI Forecast for Swing Trade Picks - newser.com | 11/18/2025 |
2 | NeuroSense Gains FDA Approval for Phase 3 ALS Trial - TipRanks | 11/24/2025 |
3 | New Alzheimers treatment from NeuroSense gets U.S. patent through 2043 - Stock Titan | 01/21/2026 |
About NeuroSense Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including NeuroSense or other stocks. Alpha measures the amount that position in NeuroSense Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 | 2025 | 2026 (projected) | Current Ratio | 0.84 | 2.21 | 2.54 | 2.41 | Net Debt To EBITDA | 0.26 | 0.33 | 0.38 | 0.37 |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards NeuroSense Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, NeuroSense Therapeutics' short interest history, or implied volatility extrapolated from NeuroSense Therapeutics options trading.
Build Portfolio with NeuroSense Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for NeuroSense Stock Analysis
When running NeuroSense Therapeutics' price analysis, check to measure NeuroSense Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuroSense Therapeutics is operating at the current time. Most of NeuroSense Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuroSense Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuroSense Therapeutics' price. Additionally, you may evaluate how the addition of NeuroSense Therapeutics to your portfolios can decrease your overall portfolio volatility.